This study assessed the incidence of serious adverse events of diabetic ketoacidosis (DKA) among patients with type 2 diabetes treated with canagliflozin.
come from the ongoing CANagliflozin cardioVascular Assessment Study (CANVAS), which is blinded and is being monitored by an independent data monitoring committee. Data from the 12 unblinded patients with serious adverse events are discussed below.
RESULTS
The incidence of serious adverse events of DKA and related events in the canagliflozin randomized clinical trial database was 0.07% (12 of 17,596). The incidence 
CONCLUSIONS
In summary, DKA and related events occurred at a low frequency in patients participating in the randomized, controlled canagliflozin type 2 diabetes clinical trial program. Although there are limited epidemiological data on the incidence of DKA in patients with type 2 diabetes, the overall incidence rates of these events in the current analysis are consistent with the broad range reported in existing observational data. Specifically, a study in Northern Sweden reported an estimated DKA incidence rate of 0.5 per 1,000 patient-years (5), and an analysis of four large U.S. commercial claims databases (i.e., the Truven MarketScan Commercial Claims and Encounters, MarketScan Medicare Supplemental Beneficiaries, the MarketScan Multistate Medicaid Database, and the Optum Clinformatics database) found a DKA incidence rate in the range of 0.32 to 2.0 per 1,000 patient-years (data on file). However, given the potential for incomplete reporting or underreporting of DKA, the incidence of DKA in patients with type 2 diabetes, including patients treated with canagliflozin and other SGLT2 inhibitors, may be underestimated. Although there were some differences in baseline characteristics between all patients and the subset of patients who developed DKA and related events, there was no clear baseline clinical phenotype that allowed the identification of specific individual patients at risk for developing DKA. Nevertheless, most patients had a known precipitating factor for DKA at the time of these events. Some reports note that patients who presented with DKA had atypically low blood glucose values; however, of the 10 patients treated with canagliflozin who presented with DKA and related events and had available blood glucose values at presentation, 9 patients had blood glucose values .250 mg/dL (13.9 mmol/L). We postulate that patients diagnosed as having .500 (.27.8)
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